USA

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The acquisition follows Stryker’s earlier move into the vascular intervention market through its approximately US$4.9 billion purchase of Inari Medical in 2025.

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.

Urodynamics assesses how the bladder, urethra, and sphincters store and release urine to identify causes of leakage or obstruction.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.